Cargando…

Barrett's Esophagus: Where Do We Stand?

Barrett's esophagus (BE) is a precursor for esophageal adenocarcinoma, which has an increased incidence rate over the last few decades. Its importance stems from the poor five-year survival of esophageal adenocarcinoma and current data that suggest a survival benefit when surveillance programs...

Descripción completa

Detalles Bibliográficos
Autor principal: Al Madi, Majid A.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702947/
https://www.ncbi.nlm.nih.gov/pubmed/19568547
http://dx.doi.org/10.4103/1319-3767.45046
_version_ 1782168818628427776
author Al Madi, Majid A.
author_facet Al Madi, Majid A.
author_sort Al Madi, Majid A.
collection PubMed
description Barrett's esophagus (BE) is a precursor for esophageal adenocarcinoma, which has an increased incidence rate over the last few decades. Its importance stems from the poor five-year survival of esophageal adenocarcinoma and current data that suggest a survival benefit when surveillance programs are implemented. In this review, we will cover the pathophysiology and natural history of BE and the different endoscopic findings. The prevalence of BE in different geographic areas and the incidence of high-grade dysplasia and adenocarcinoma in this patient population is reviewed. Recent recommendation for screening and surveillance of BE has been covered in this review as well as the efficacy of nonconventional imaging modalities and endoscopic ablation therapies.
format Text
id pubmed-2702947
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-27029472009-06-30 Barrett's Esophagus: Where Do We Stand? Al Madi, Majid A. Saudi J Gastroenterol Review Article Barrett's esophagus (BE) is a precursor for esophageal adenocarcinoma, which has an increased incidence rate over the last few decades. Its importance stems from the poor five-year survival of esophageal adenocarcinoma and current data that suggest a survival benefit when surveillance programs are implemented. In this review, we will cover the pathophysiology and natural history of BE and the different endoscopic findings. The prevalence of BE in different geographic areas and the incidence of high-grade dysplasia and adenocarcinoma in this patient population is reviewed. Recent recommendation for screening and surveillance of BE has been covered in this review as well as the efficacy of nonconventional imaging modalities and endoscopic ablation therapies. Medknow Publications 2009-01 /pmc/articles/PMC2702947/ /pubmed/19568547 http://dx.doi.org/10.4103/1319-3767.45046 Text en © The Saudi Journal of Gastroenterology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Al Madi, Majid A.
Barrett's Esophagus: Where Do We Stand?
title Barrett's Esophagus: Where Do We Stand?
title_full Barrett's Esophagus: Where Do We Stand?
title_fullStr Barrett's Esophagus: Where Do We Stand?
title_full_unstemmed Barrett's Esophagus: Where Do We Stand?
title_short Barrett's Esophagus: Where Do We Stand?
title_sort barrett's esophagus: where do we stand?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702947/
https://www.ncbi.nlm.nih.gov/pubmed/19568547
http://dx.doi.org/10.4103/1319-3767.45046
work_keys_str_mv AT almadimajida barrettsesophaguswheredowestand